Dr. Cohen talks about the potential for bringing CAR T-cell therapy to heavily-pretreated myeloma patients, as well as the potential toxicities.
Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma
Recent Articles
Hemophilia Drug Receives Priority Review From FDA
The U.S. Food and Drug Administration (FDA) has granted priority review to Roche’s biosimilar for emicizumab, a monoclonal antibody to treat children and adults...
Layoffs Suggest Deeper Problems Within Watson Health
Watson Health, an IBM project, cut staff from recently acquired data companies Explorys, Phytel, and Truven Health Analytics in an extensive round of layoffs...
FDA Approves First Pegfilgrastim Biosimilar
The U.S. Food and Drug Administration (FDA) has approved pegfilgrastim-jmdb, a biosimilar version of pegfilgrastim that is indicated to decrease the duration of neutropenia...
AMA Releases Opioid Task Force Progress Report
The American Medical Association’s (AMA’s) Opioid Task Force 2018 Progress Report shows progress toward reversing the epidemic. Most significantly, opioid prescriptions have fallen across...
CMS Introduces Medicaid Scorecard
Centers for Medicare and Medicaid Services Administrator Seema Verma, MPH, unveiled a scorecard for Medicaid and the Children’s Health Insurance Program (CHIP). The scorecard...
Current Issue
June 2018, Volume 4, Issue 7
This issue features a look at gaining oral parity for cancer medications, the unavoidable "bubbles" in which people live and work, and more.
